Literature DB >> 27072998

Value of Surgical Resection in Patients with Newly Diagnosed Grade III Glioma Treated in a Multimodal Approach: Surgery, Chemotherapy and Radiotherapy.

Federico Pessina1, Pierina Navarria2, Luca Cozzi3, Anna Maria Ascolese2, Matteo Simonelli4, Armando Santoro4, Stefano Tomatis2, Marco Riva1, Enrica Fava1, Marta Scorsetti2, Lorenzo Bello1.   

Abstract

BACKGROUND: Current treatments in grade III gliomas include surgery, radiotherapy, and chemotherapy. The value of the entity of surgical resection remains an open question. The aim of this evaluation was to analyze the impact of extent of resection (EOR) and residual tumor volume (RTV) on progression-free survival (PFS) and overall survival (OS) in patients with newly diagnosed grade III gliomas.
METHODS: Overall, 136 patients were included in this evaluation. EOR and RTV were defined in all patients on postoperative volumetric magnetic resonance imaging, with EOR being defined as the rate of surgical resection, and RTV as contrast-enhancing RTV (CE-RTV) and fluid-attenuated inversion recovery (FLAIR) RTV. A threshold of EOR and RTV was recorded using increments of 2 % and 1 cm(3).
RESULTS: EOR and RTV were the only clinical variables influencing PFS and OS. The EOR cut-off value for conditioning survival was 76 %. For EOR ≥76 % or <76 %, the 5- to 10-year PFS was 57 % and 18 % versus 0 % (p = 0.03), and 5- to 10-year OS was 68 % and 42 % versus 0 % (p = 0.06), respectively. Additionally, the RTV cut-off value was 3 cm(3); for RTV <3 cm(3) or >3 cm(3), 5- to 10-year PFS was 64.3 % and 48.2 % versus 42 % and 0 % (p = 0.02), and 5- to 10-year OS was 66.8 % and 33.4 % versus 56 % and 0 % (p = 0.3), respectively. RTV was a more significant parameter conditioning PFS and OS than EOR (p = 0.04), and the presence of CE-RTV was an unfavorable prognostic factor compared with FLAIR-RTV.
CONCLUSIONS: In heterogeneous lesions from a radiological point of view as WHO grade III gliomas if a complete removal is not possible, it would be advisable to maximize the removal of enhancing areas, possibly with an EOR >76 % and an RTV <3 cm(3).

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27072998     DOI: 10.1245/s10434-016-5222-3

Source DB:  PubMed          Journal:  Ann Surg Oncol        ISSN: 1068-9265            Impact factor:   5.344


  12 in total

1.  Maximize surgical resection beyond contrast-enhancing boundaries in newly diagnosed glioblastoma multiforme: is it useful and safe? A single institution retrospective experience.

Authors:  Federico Pessina; Pierina Navarria; Luca Cozzi; Anna Maria Ascolese; Matteo Simonelli; Armando Santoro; Elena Clerici; Marco Rossi; Marta Scorsetti; Lorenzo Bello
Journal:  J Neurooncol       Date:  2017-07-08       Impact factor: 4.130

Review 2.  Functional MRI for Surgery of Gliomas.

Authors:  Antonella Castellano; Sara Cirillo; Lorenzo Bello; Marco Riva; Andrea Falini
Journal:  Curr Treat Options Neurol       Date:  2017-08-23       Impact factor: 3.598

3.  Role of surgical resection in recurrent glioblastoma: prognostic factors and outcome evaluation in an observational study.

Authors:  Federico Pessina; Pierina Navarria; Luca Cozzi; Stefano Tomatis; Marco Riva; Anna Maria Ascolese; Armando Santoro; Matteo Simonelli; Lorenzo Bello; Marta Scorsetti
Journal:  J Neurooncol       Date:  2016-11-08       Impact factor: 4.130

Review 4.  Surgical oncology for gliomas: the state of the art.

Authors:  Nader Sanai; Mitchel S Berger
Journal:  Nat Rev Clin Oncol       Date:  2017-11-21       Impact factor: 66.675

5.  Knockdown of long non-coding RNA LINC00467 inhibits glioma cell progression via modulation of E2F3 targeted by miR-200a.

Authors:  Shuzi Gao; Haixia Duan; Dezhu An; Xinfeng Yi; Jiayan Li; Changchun Liao
Journal:  Cell Cycle       Date:  2020-07-20       Impact factor: 4.534

6.  Expression of microRNA-184 in glioma.

Authors:  Xiao-Ben Wu; Wei Yang; Gang Fan; Wan-Run Lin; Fang Liu; Zhi-Ming Lu
Journal:  Oncol Lett       Date:  2017-11-13       Impact factor: 2.967

7.  Recurrence patterns after maximal surgical resection and postoperative radiotherapy in anaplastic gliomas according to the new 2016 WHO classification.

Authors:  Jung Ho Im; Je Beom Hong; Se Hoon Kim; Junjeong Choi; Jong Hee Chang; Jaeho Cho; Chang-Ok Suh
Journal:  Sci Rep       Date:  2018-01-15       Impact factor: 4.379

8.  Integrated mRNAseq and microRNAseq data analysis for grade III gliomas.

Authors:  Junqiang Dai; Zhitong Bing; Yinian Zhang; Qiao Li; Liang Niu; Wentao Liang; Guoqiang Yuan; Lei Duan; Hang Yin; Yawen Pan
Journal:  Mol Med Rep       Date:  2017-09-20       Impact factor: 2.952

Review 9.  A comprehensive approach in high-grade glioma management: position statement from the Neuro-Oncology Scientific Club (NOSC), Shiraz, Iran.

Authors:  Mansour Ansari; Ahmad Mosalaei; Niloufar Ahmadloo; Alireza Rasekhi; Bita Geramizadeh; Ali Razmkon; Kazem Anvari; Mohammad Afarid; Ali Dadras; Leila Nafarieh; Mohammad Mohammadianpanah; Hamid Nasrolahi; Seyed Hasan Hamedi; Shapour Omidvari; Mohammad Nami
Journal:  Ger Med Sci       Date:  2017-02-28

10.  Development of a novel morphological paclitaxel-loaded PLGA microspheres for effective cancer therapy: in vitro and in vivo evaluations.

Authors:  Zongrui Zhang; Xinyu Wang; Binbin Li; Yuanjing Hou; Jing Yang; Li Yi
Journal:  Drug Deliv       Date:  2018-11       Impact factor: 6.419

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.